Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company (MDCO)

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) announced today that Glenn Sblendorio, President and Chief Financial Officer, will retire from the company effective March 31, 2016. As of January 1, 2016, Mr. Sblendorio will be relinquishing his seat on the Board of Directors and his operational responsibilities will be assumed by others within the company. William O'Connor, Senior Vice President & Chief Accounting Officer, who has been with The Medicines Company since 2006, will succeed Mr. Sblendorio as Chief Financial Officer.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.